Fig 1: Immunostaining of IL-26 in bronchoalveolar lavage (BAL) cells from lung transplant recipients with (n = 5; a–c and e) and without (n = 4; d) bronchiolitis obliterans (BOS). Immunostaining was performed using a an IgG2b isotype control antibody, a polyclonal CD68 antibody (b; brown), a monoclonal specific IL-26 antibody (c; purple) or a monoclonal specific IL-26 antibody in combination with a polyclonal CD68 antibody (d and e)
Fig 2: Interleukin (IL)-26 protein concentration (logarithmic scale) in cell-free bronchoalveolar lavage (BAL) fluid from lung transplant recipients (LTRs) with (n = 20) and without (n = 20) bronchiolitis obliterans syndrome (BOS) quantified by enzyme-linked immunosorbent assay (ELISA). Bars represent the median
Fig 3: Interleukin (IL)-26 protein concentration (logarithmic scale) in cell-free bronchoalveolar lavage fluid (BAL) from lung transplant recipients (LTRs) with (n = 12) and without (n = 12) acute rejection (AR) quantified by enzyme-linked immunosorbent assay (ELISA). Bars represent the median
Fig 4: Interleukin (IL)-26 protein concentration (logarithmic scale) in cell-free bronchoalveolar (BAL) fluid from lung transplant recipients (LTRs) with (n = 10) or without (n = 10) bronchiolitis obliterans syndrome (BOS) quantified by enzyme-linked immunosorbent assay (ELISA). Time one and two before and time three at BOS diagnosis (with corresponding time points in the BOS free group
Supplier Page from CUSABIO Technology LLC for Human Interleukin 26,IL-26 ELISA Kit